Skip to main content
Top
Published in: Journal of Hematology & Oncology 1/2020

Open Access 01-12-2020 | NSCLC | Retraction Note

Retraction Note to: MicroRNA-330-3p promotes cell invasion and metastasis in non-small cell lung cancer through GRIA3 by activating MAPK/ERK signaling pathway

Authors: Chun-Hua Wei, Gang Wu, Qian Cai, Xi-Can Gao, Fan Tong, Rui Zhou, Rui-Guang Zhang, Ji-Hua Dong, Yu Hu, Xiao- Rong Dong

Published in: Journal of Hematology & Oncology | Issue 1/2020

Login to get access

Excerpt

In accordance with the guidelines published by COPE, the authors have retracted this article [1] because of significant concerns regarding a number of Figures presented in this work. In Fig. 3C and 3D there are duplications in the NC and NC-LV groups in the H460 cells, NC-LV, OE-miR-330-3p-LV and anti-miR-330-3p-LV groups in the H1975 cells. In Fig. 7D, the H1975/NC-LV Vec image has been duplicated from the H460/NC image in Fig. 3C. There are multiple duplications throughout Fig. 6, and there are duplications in Fig. 9D (OE-miR-330-3p-LV and OE-miR-330-3p-LV + U0126 groups in the H460 cells, OE-miR-330-3p-LV group in the H1975 cells). The data reported in this article are therefore unreliable. …
Metadata
Title
Retraction Note to: MicroRNA-330-3p promotes cell invasion and metastasis in non-small cell lung cancer through GRIA3 by activating MAPK/ERK signaling pathway
Authors
Chun-Hua Wei
Gang Wu
Qian Cai
Xi-Can Gao
Fan Tong
Rui Zhou
Rui-Guang Zhang
Ji-Hua Dong
Yu Hu
Xiao- Rong Dong
Publication date
01-12-2020
Publisher
BioMed Central
Keywords
NSCLC
NSCLC
Published in
Journal of Hematology & Oncology / Issue 1/2020
Electronic ISSN: 1756-8722
DOI
https://doi.org/10.1186/s13045-020-00969-0

Other articles of this Issue 1/2020

Journal of Hematology & Oncology 1/2020 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine